comparemela.com

Latest Breaking News On - Remedy pharmaceuticals - Page 1 : comparemela.com

Biogen Looks To Bulk Up Rare Disease Portfolio With $7 3 Billion Acquisition

Biogen will buy Reata Pharmaceuticals and its Friedreich s ataxia drug in a $7.3 billion deal.

United statesAduhelm forbesConvergence pharmaceuticalsNational health serviceDrug administrationReata pharmaceuticalsRemedy pharmaceuticalsNightstar therapeuticsNational healthNew alzheimerDown after struggles with alzheimerDrug aduhelmWhere barbieIndependent women part i

FDA grants accelerated approval for Biogen s ALS drug tofersen

The FDA has granted accelerated approval for Biogen’s Qalsody (tofersen): making it the first treatment to target a genetic cause of ALS.

United statesChristophera viehbacherQalsody neurofilamentsCenters for diseaseDisease controlNew drug applicationRemedy pharmaceuticalsBio developments

Biogen : Strong progress toward three potential launches in 2023; Company reports first quarter 2023 results and reaffirms full year 2023 guidance - Form 8-K

Strong progress toward three potential launches in 2023; Company reports first quarter 2023 results and reaffirms full year 2023 guidance First. | April 25, 2023

Chuck trianoChristophera viehbacherAdam keeneyJack coxSamsung bioepisUs veteran health administrationBiogen incAdvisory committeeExchange commissionHead of corporate developmentNet income attributable to biogen incDevelopment expensePriority reviewHealth administrationSage therapeuticsZuranolone new drug application

Biogen : Reports First Quarter 2023 Results

Press Release Cambridge, Mass. - Apr. 25, 2023 Strong progress toward three potential launches in 2023; Company. | April 25, 2023

United kingdomSamsung bioepisAdam keeneyChristophera viehbacherChuck trianoBiogen inc nasdaqBiogen incUs veteran health administrationHead of corporate developmentAdvisory committeePress releaseHealth administrationSage therapeuticsNew drug applicationPriority reviewInvestor relations

Cambridge-Based Biogen Halts Work on Several Drugs as It Awaits FDA Decisions

Biogen halts work on several drugs as it awaits FDA decisions

United kingdomChristopher viehbacherBiogen incRemedy pharmaceuticalsBoston business journal

vimarsana © 2020. All Rights Reserved.